NuCana (NASDAQ:NCNA) Stock Jumps 0.8% – Time to Buy?

NuCana PLC Sponsored ADR (NASDAQ:NCNA) rose 0.8% on Thursday. The company traded as high as $1.34 and last traded at $1.32. Approximately 9,226 shares traded hands during trading, a decline of 90% from the average session volume of 88,672 shares. The stock had previously closed at $1.31.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of NuCana in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, NuCana presently has a consensus rating of “Sell”.

NuCana Trading Up 0.8%

The firm has a market capitalization of $5.49 million, a P/E ratio of -0.35 and a beta of 2.23. The company has a 50-day moving average of $1.39 and a 200-day moving average of $1.69.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.99) earnings per share for the quarter, beating the consensus estimate of ($2.65) by $1.66.

NuCana Company Profile

NuCana plc is a clinical-stage biopharmaceutical company focused on developing cancer treatments designed to improve the delivery and activity of nucleoside analog medicines. The company’s proprietary ProTide technology is intended to help overcome biological barriers that can limit the effectiveness of conventional nucleoside-based therapies.

NuCana’s lead investigational product, NUC-3373, is a ProTide-based therapy derived from 5-fluorouracil (5-FU), a commonly used chemotherapy agent.